DGAP-News

Vita 34 AG: Increase in Profitability in Q1 Confirms Positive Growth Outlook 2014 - Seite 2

million after the first three months of 2014, following EUR 0.1 million at
the end of Q1 2013. The period result increased to EUR 204k, after having
been negative at EUR -20k the prior year.

Dr. André Gerth, Chairman of the Management Board at Vita 34 AG, was
pleased with the result and development of the company: "We have further
increased profitability with stable revenues. The strong EBITDA margin of
18.3 percent underscores the profitability of our business activities. We
have confirmed our market leadership in the German-speaking countries with
the 100,000th storage of a stem cell preparation." For example, Vita 34 was
able to celebrate the 100,000th storage of a stem cell preparation, among
them the 1,500th storage with a donation option, in Leipzig in March 2014.
Moreover, during the reporting period the 26th transplant using a stem cell
preparation stored at Vita 34 was conducted. This outstanding application
rate of some 43 percent of all therapeutic stem cell applications reported
to Cord Blood Europe reflects the high quality of the preparations stored
at Vita 34.

Dr. Gerth is optimistic about future development: "During the reporting
period we continuously worked towards expanding our market position. Here,
the focus lays in particular on moving the storage of umbilical cord tissue
in Germany and with our international partners forward. We are now the only
stem cell bank in Germany that has a permit not only for the storage of
umbilical cord blood, but also umbilical cord tissue. We will consistently
use the resulting potential revenues and income."

Accordingly, Vita 34 has applied for permit for collecting tissue with all
of the 27 responsible agencies within Germany, in order to enter into
contracts for collecting umbilical cord tissue with all partner clinics in
Germany. At the end of the reporting period, the corresponding permits had
been received from 12 agencies. In addition, Vita 34 received an import
license for umbilical cord tissue from Switzerland in accordance with Sec.
72b German Pharmaceuticals Act (AMG) and a collection permit for umbilical
cord blood in accordance with Sec. 19 (2) of the Austrian Tissue Safety Act
(GSG) in Austria during Q1 2014. Vita 34 has advanced the introduction
umbilical cord tissue storage with our respective partners in Slovenia,
Romania, Bulgaria, Macedonia and Croatia. The first tissue storages from
Switzerland, Macedonia and Bulgaria have already taken place.

In light of the positive development of business, Vita 34 AG confirms the
prognosis made for 2014 in the 2013 annual report. This foresees a moderate